* If you want to update the article please login/register
"The investigators intend to investigate whether sleep changes in sleep can influence pain and pain-related outcomes in adults with Sickle Cell Disease. " Pain and sleep are closely related, in that anxiety disturbs sleep and disturbed sleep contributes to insomnia, which also raises the risk of experiencing chronic pain. Pain modulation is often interrupted by chronic pain, owing to the demands placed on cognitive resources, which are likely to persistent insomnia. Particularly because sleep disruption is a mutable risk factor, the possibility for improved sleep to reduce pain and CS requires further investigation. Using brain imaging in SCD, the aim is to determine whether sleep treatment improves pain symptoms in SCD, and whether chronic sleep treatment improves cognitive connectivity of cognitive and pain modulatory networks.
Source link: https://clinicaltrials.gov/ct2/show/NCT03150433
"The investigators found that nearly 20% of adult SCD patients had elevated blood pressures for both biomarkers, defined as a TRV 2. 5 meters per second and a NT-proBNP 2. 0 pg/mL, and that the 12-month mortality rate is 7. 9% in this group, relative to 0. 59 in patients with normal TRV or NT-proBNP, with a risk ratio for hospitalization of 1. 6 in two large registry cohorts with SCD patients with a simple screening report of TRV and NT-proBNP will show around 20% of patients with SCD who are at risk of death and hospitalization, according to this. parafusions are administered by either simple or exchange transfusion, the patient's blood is removed from the blood and replaced with transfused red blood cells, according to the hospital's chief. Researchers estimate that monthly exchange transfusion therapy would reduce disease progression, improve fitness, and avoid interval episodes of vaping acutely elevates pulmonary pressures and lead to right heart failure. Compared to the norm of care among 150 adult high risk SCD patients, the investigators intend to perform a scientific trial to see the effects of automated exchange blood transfusion on patient morbidity and mortality. Despite the safety and widespread use of erythrocytapheresis in adult patients with SCD, there is no consensus or quality evidence on its use to enhance outcomes in our elderly high-risk SCD patients with progressive end-organ dysfunction. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT04084080
"The interrogating antibody coats the microchannel surface and captures the cell population of concern, without processing, incubation, or in vitro manipulation. " Cellular adhesion to experimental biological surfaces that are made up of subcellular components can also be quantified by the SCD biochip. The SCD biochip is both inexpensive and adaptable, whereby the population of concern is kept on the chip and quantitated in situ. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT02824471
"To assess the safety and feasibility of hematopoietic stem cell transplantation in adult patients with Sickle Cell Disease" after treatment with fludarabine in adult patients with Sickle Cell Disease. SCD's Secondary Objective The objective of this research, which is linked to the development of disease-free and overall longevity in both MSD and alternate graft donors. To determine fertility in matched sibling and alternate graft donor recipients In SCD, compare GVHD rates. Before and during HSCT in SCD, to assess hematopoiesis and erythropoiesis. Allogeneic Transplantation Modulation of SCD Phenotype Modulation by Allogeneic Transplantation Modulation of SCD Phenotype by Allogeneic Transplantation. Procedures: The trial will begin with at least ten patients and up to 25 patients. During what is described as the dose-limiting toxicity period, researchers will monitor the patients. Before the DLT period is complete, the study will not enroll new patients. If at least three of the ten patients enrolled do not benefit, the maximum tolerated dose will be considered exceeded. Patients will receive a stem cell transplant from a genetically matched donor after the DLT period is complete, and patients will receive a stem cell transplant from a genetically matched donor. To prepare for the transplant patients, the transplant recipients will have to receive either a perfectly aligned sibling donor, a closely related donor, a cord blood donor rabbit antithymocyte globulin fludarabine cytoxan Fludarabine. This is the main drug tested in this research total body irradiation tacrolimus, mycophenolate, and/or methotrexate. They are supposed to decrease your chances of getting GVHD and rejecting the donor cells, which are both designed to improve your chances of getting GVHD and destroying the donor cells. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT02065596
"This protocol will enable the establishment of a database of biospecimens from people affected by sickle cell disease to identify and analyze the disease's causes, as well as assist in the diagnosis and analysis of the pathogenesis and natural history of the disease. " Any surgical care or additional tests/analyses that are suggested or provided to the patient would be consistent with established procedures of practice and will be performed in consultation with the patient's referring physician. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT00081523
"VTE patients with Sickle Cell Disease have an elevated risk of VTE as the disease itself is a hypercoagulable condition. " According to studies, up to 12% of patients with SCD have VTE events [deep vein thrombus or pulmonary embolism or both] early in life by age 40, the bulk of which are unprovoked. Patients with a VTE have a 24. 1% risk of recurrence over 5 years, according to a SCD patient who develops a VTE. A history of a VTE in SCD is correlated with increased mortality risk. Specifically, the intravascular tissue factor converts factor X to factor Xa, resulting in the first thrombin burst that may cause intravascular thrombosis. Patients with VTE and/or recurrent VTE are therefore more likely to have more tissue factor positive extracellular vesicles and plasma tissue factor procoagulant activity than SCD patients without VTE. It becomes a high priority to study thrombogenic risk and specifically identifying those SCD patients who are at the highest risk of VTE recurrence. In addition, people with sickle cell disease are prone to thrombosis, but no studies have looked at thrombotic risk in these individuals. In contrast to ethnically matched controls, in the current study, plasma tissue factor positive extracellular vesicles and tissue factor production are elevated among SCD patients with VTE and in patients with Sickle Cell Trait.
Source link: https://clinicaltrials.gov/ct2/show/NCT04349189
"Episodic pain is the most common acute morbidity and the leading cause of hospitalization in patients with sickle cell disease. " The advent of acute sickle pain is attributed to a variety of events that include inflammation and thrombosis, as well as ischemia-reperfusion injury. Cell-free DNA has been shown to be present in plasma of healthy people, but it is inflamed disease and conditions characterized by increased cell death by necrosis or apoptosis. In fact, we have previously reported that cfDNA in patients with sickle cell disease soared sharply during acute painful episodes. During acute sickle pain, a dramatic rise in sickled red blood cells and hemolysis has also been observed. Although there have been many studies into cytokines and chemokines in steady state and acute sickle cell disease, no comprehensive investigation has been done into how the immune markers correlate with quantitative measurements and profile of cfDNA. We want to analyze cfDNA from patient's plasma of patients with SCD in stable condition, as well as during painful crises to derive information on tissue damage. In addition, we'd like to investigate if there is a distinct cell-free DNA and inflammation signature in SCD in steady state and during acute vaping crises. Overall, this review provides the opportunity to identify new biomarkers of sickle cell pain in the disease epidemic and to predict disease severity and prognosis. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT03049475
"Such studies have corroborated the MPL of healthy donor RBCs to be about 115 days, while sickle cell disease patients have a more variable but shorter MPL of around 32 days. " This report will examine the population methodology used to determine MPL in subjects with SCD, patients with sickle cell disease, and healthy donors without SCD. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT04476277
"Thus, the risks of a cure in SCD must be considered against the benefits of a treatment, which include lung function stabilization and improved tricuspid regurgitant jet velocity [TRJV]. The investigators will perform the following hypotheses: 1a: myeloablative curative therapies for children with SCD will result in progressive pulmonary and renal dysfunction in children with SCD receiving standard therapy; 2b: nonmyeloablative HSCT for adults with SCD will result in a dramatic decline in FEV1 in comparison to adults with SCD who receive standard therapy; 3b: Myelobacterial HSCT will result in an increase in eGFR pharmac;.
Source link: https://clinicaltrials.gov/ct2/show/NCT05153967
"Desmopressin is an oral drug that increases water reabsorption in the kidneys. " Chronic sickling episodes that result in kidney injury may result in permanent injury and can make this therapy ineffective in sickle cell disease. "This trial will inform pediatric sickle cell doctors if desmopressin is a safe therapy for bed wetting in the investigators' patients. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT02636387
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions